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ABSTRACT 
 
Omapatrilat, a vasopeptidase inhibitor, inhibits both neutral endopeptidase (NEP) and 
angiotensin converting enzyme (ACE) with similar potency. The aim of this study 
was to investigate whether omapatrilat prevents or reverses cardiovascular 
remodelling and hypertension in deoxycorticosterone acetate (DOCA)-salt rats. Male 
Wistar rats (313±2 g, n=114) were uninephrectomized (UNX) with or without further 
treatment with DOCA and 1% NaCl in the drinking water. Compared with UNX 
control rats, DOCA-salt rats developed hypertension, cardiovascular hypertrophy, 
perivascular and interstitial cardiac fibrosis and inflammation, endothelial dysfunction 
and prolongation of ventricular action potential duration within 4 weeks. 
Administration of omapatrilat (40 mg/kg/day po) for two weeks commencing two 
weeks after surgery attenuated the development of cardiovascular hypertrophy, 
inflammation, fibrosis and ventricular action potential prolongation. In contrast, 
omapatrilat treatment did not lower systolic blood pressure nor improve endothelial 
dysfunction. We conclude that the renin-angiotensin-aldosterone, natriuretic peptide 
and bradykinin systems are directly involved in the pathogenesis of cardiovascular 
remodelling in the DOCA-salt model of hypertension in rats, which may be 
independent of their effects on blood pressure. 
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INTRODUCTION 
 
Dual inhibition of angiotensin converting enzyme (ACE) and neutral endopeptidase 
(NEP), termed vasopeptidase inhibition, augments the beneficial actions of natriuretic 
peptides, adrenomedullin and bradykinin on regulating blood pressure and 
cardiovascular function, whilst preventing the detrimental effects of angiotensin II 
(1). Vasopeptidase inhibitors, which include omapatrilat, offer a new approach to the 
treatment of hypertension and heart failure (2-4). In experimental hypertension, 
omapatrilat lowered blood pressure irrespective of renin and volume status (5) and the 
response elicited was significantly greater than selective inhibition of either NEP or 
ACE alone (6,7). Blood pressure control alone, however, is no longer considered 
adequate therapeutic management of hypertensive patients. Novel antihypertensives 
should also exert beneficial effects on cardiovascular remodelling and other 
associated end-organ damage, key risk factors in the morbidity and mortality of heart 
disease. 
 
Considering the complex interplay between the neurohumoral systems, omapatrilat 
represents a potentially important therapeutic approach to hypertension and associated 
end-organ damage (1-5). It has the advantage of blocking a mechanism inducing 
remodelling via ACE inhibition, whilst, as a NEP inhibitor, simultaneously 
stimulating a mechanism to reduce remodelling by reducing the degradation of 
natriuretic peptides, bradykinin and adrenomedullin. One potential drawback is that 
NEP is also involved in the degradation of endothelin (8,9) and thus NEP inhibition 
could be deleterious by increasing circulating levels of this potent vasoconstrictor and 
trophic peptide.   
 
This study has administered the potent, balanced vasopeptidase inhibitor, omapatrilat, 
to DOCA-salt hypertensive rats for two weeks starting two weeks after induction of 
hypertension. This is a well-established model of volume-dependent hypertension 
(10), characterized by low plasma renin activity and elevated atrial natriuretic peptide 
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(ANP) levels (11). In addition, increased endothelin is believed to be a key 
mechanism for the induction of cardiac and vascular damage in DOCA-salt 
hypertensive rats via augmentation of vascular superoxide production by NADPH 
oxidase (12-14). Our aim was to determine whether omapatrilat prevents the further 
development of hypertension and cardiovascular remodelling, reverses existing 
structural changes and normalises cardiovascular function in this rat model of human 
hypertension. 
 
METHODS 
 
Ethical clearance 
All experimentation was approved by the Animal Experimentation Ethics Committee 
of The University of Queensland under the guidelines of the National Health and 
Medical Research Council of Australia. 
 
DOCA-salt hypertensive rats 
Male Wistar rats weighing 300-330 grams (~8 weeks old) were obtained from the 
Central Animal Breeding House of The University of Queensland. All rats were 
uninephrectomied under anaesthesia with intraperitoneal tiletamine (25 mg/kg) and 
zolazepam (25 mg/kg)(Zoletil®) combined with xylazine (10 mg/kg)(Ilium Xylazil®). 
Kidneys were visualised by a left lateral abdominal incision. The left kidney was 
removed after ligation of adjoining renal vasculature and ureter with sutures. 
Uninephrectomized rats were given either no further treatment (UNX rats) or 1% 
NaCl in the drinking water with subcutaneous injections of deoxycorticosterone 
acetate (DOCA; 25mg in 0.4ml dimethylformamide every fourth day) (DOCA-salt 
rats). After 14 days, subgroups of UNX and DOCA-salt rats received daily oral 
gavaging of omapatrilat (40 mg/kg) or no treatment, for a further 14 days. 
Experiments were performed either 14 or 28 days after surgery.  
 
Assessment of physiological parameters 
Systolic blood pressure was measured by tail-cuff plethysmography (ADInstruments) 
in rats lightly anaesthetised with intraperitoneal tiletamine (10 mg/kg) and zolazepam 
(10 mg/kg). Rats were euthanased with pentobarbitone (200 mg/kg ip). After adequate 
anaesthesia and prior to death, blood was taken from the abdominal vena cava, just 
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caudal to the insertion of renal veins, centrifuged and the plasma immediately frozen 
for subsequent measurement of sodium and potassium concentrations by flame 
photometry. The heart was removed and weighed immediately after death, and heart 
weight was expressed as a ratio of the tissue weight (mg) to the total body weight (g). 
 
Isolated Langendorff heart preparation 
Rats were anaesthetized with sodium pentobarbitone (100 mg kg-1 ip) and heparin 
(200 IU) was administered via the femoral vein. After allowing two minutes for the 
heparin to circulate, the heart was excised and placed in cooled (0°C) crystalloid 
perfusate (modified Krebs-Henseleit solution of the following composition in mM: 
NaCl 119.1, KCl 4.75, MgSO4 1.19, KH2PO4 1.19, CaCl2 2.16, NaHCO3 25.0, 
glucose 11.0). A cannula was then placed in the heart with its tip immediately above 
the coronary ostia of the aortic stump. The cannula was used to perfuse the heart in a 
non-recirculating Langendorff fashion at 100cm of hydrostatic pressure. The 
perfusate temperature was maintained at 37°C and bubbled with 95% O2 / 5% CO2. 
The apex of the heart was pierced to facilitate thebesian drainage and paced at 250 
bpm by electrodes placed on the surface of the right atrium.   
 
Left ventricular developed pressure was measured using a balloon catheter inserted 
into the left ventricle through the mitral orifice. The catheter was connected via a 
three-way tap to a micrometer syringe and to a MLT844 Physiological Pressure 
Transducer (ADInstruments) and PowerLab data acquisition unit (ADInstruments). 
The outer diameter of the catheter was similar to the mitral annulus to prevent 
ejection of the balloon during the systolic phase. After a 5 minute stabilization period, 
steady-state left ventricular pressure was recorded from isovolumetrically beating 
hearts. Increments in balloon volume were applied to the heart with left ventricular 
end-diastolic pressure recorded at approximately 0, 5, 10, 15, 20 and 30 mmHg. At 
the end of the experiment, the atria and right ventricle were dissected away leaving 
the left ventricle and septum, which were blotted then weighed. Myocardial diastolic 
stiffness was calculated as the diastolic stiffness constant (k, dimensionless), the slope 
of the linear relation between tangent elastic modulus (E, dyne/cm2) and stress (σ, 
dyne/cm2) (15, 16).  
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Isolated thoracic aortic rings 
Thoracic aortic rings (approximately 4 mm in length) were suspended in 25mL organ 
baths with a resting tension of 10 mN. Force of contraction was measured 
isometrically with Grass FT03C force transducers. Cumulative concentration-
response curves were performed for noradrenaline and either acetylcholine or sodium 
nitroprusside in the presence of a submaximal (~70%) contraction to noradrenaline.  
 
Quantification of left ventricular collagen 
Collagen content was determined by image analysis of picrosirius red-stained sections 
of the hearts (17). Tissue collagen content was also measured by a modified 
hydroxyproline assay (18). Approximately 5.0 mg samples of left ventricle were dried 
for 6 hours at 40°C. Tissues and standards were then hydrolyzed in 6M HCl at 107°C 
for 18 hours. The acid was blown off by filtered compressed air and the hydrolysate 
reconstituted in distilled water. Chloramine T reagent was added to each sample for 
the oxidation step to progress, followed by Ehrlich’s reagent to enable chromophore 
development. Absorbance of each sample was read at 550nm in a spectrophotometer 
and hydroxyproline content established from a standard curve. 
 
Width of media in thoracic aorta 
The width of the media in the thoracic aorta of rats was measured by image analysis 
of picrosirius red-stained sections. Section preparation, staining, image acquisition 
and analysis were similar to those mentioned above. Three different cross-sectional 
areas of each aorta were measured and the results averaged. 
 
Grading of inflammation in left ventricle 
The degree of left ventricular inflammation was determined by blinded semi-
quantitative analysis of haematoxylin and eosin-stained transverse sections. Slides 
were visualised under bright field illumination at 40x magnification. A zero to four 
grading scale was used to quantify the degree of inflammatory cell infiltration in the 
left ventricle. 0 = no inflammatory cells present; 1 = low level of inflammatory cells 
throughout the left ventricle; 2 = moderate levels of inflammatory cells throughout the 
left ventricle and concentrated in mild scarring; 3 = high levels of inflammatory cells 
throughout the left ventricle and concentrated in moderate scarring; 4 = high levels of 
inflammatory cells throughout the left ventricle and concentrated in heavy scarring. 
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 Microelectrode studies of isolated left ventricular papillary muscles 
Electrophysiological recordings of cardiac action potentials were obtained by 
microelectrode single cell impalements of ex vivo, left ventricular papillary muscles, 
as described previously (17). 
 
Data analysis 
All results are given as mean ± SEM. The negative log EC50 of the increase in force of 
contraction in mN was determined from the concentration giving half-maximal 
responses in individual concentration-response curves. These results were analysed by 
one-way analysis of variance followed by the Tukey post test to determine differences 
between treatment groups; p<0.05 was considered significant. 
 
Drugs 
Omapatrilat (BMS-186716) was provided by Bristol-Myers Squibb, Princeton, NJ, 
USA. Deoxycorticosterone acetate, 4-aminopyridine, acetylcholine, sodium 
nitroprusside and noradrenaline were purchased from Sigma Chemical Company, St 
Louis, MO, USA. Noradrenaline, sodium nitroprusside and acetylcholine were 
dissolved in distilled water and deoxycorticosterone acetate was dissolved in 
dimethylformamide with mild heating.  
 
 
RESULTS 
 
Over the four-week treatment period, DOCA-salt rats gained significantly less weight 
than UNX controls and became hypernatraemic, hypokalaemic and hypertensive 
(Table 1, Figure 1). These rats developed significant cardiac remodelling, including 
left ventricular and aortic hypertrophy, inflammation, perivascular collagen 
deposition and cardiac action potential prolongation, in addition to an increased 
remnant kidney wet weight (Tables 1 and 2, Figure 2). These changes were already 
evident after two weeks of DOCA-salt administration. An additional two weeks of 
DOCA-salt administration saw further significant increases in these parameters of 
cardiac remodelling, as well as elevations in left ventricular interstitial collagen and 
hydroxyproline contents and kidney weight (Table 1, Figure 2).  
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 Omapatrilat therapy for two weeks commencing two weeks after surgery attenuated 
the additional increase in left ventricular wet weight and prevented further cardiac 
collagen deposition and inflammatory cell infiltration without changes in body 
weight, systolic blood pressure or kidney weight (Tables 1, Figures 1 and 2). In 
addition, further aortic medial hypertrophy in DOCA-salt rats was prevented by 
omapatrilat intervention (Table 1). Omapatrilat did not significantly decrease diastolic 
stiffness in hypertensive rats (Table 1). The vasopeptidase inhibitor was without 
effect on plasma sodium concentrations, but normalised plasma potassium 
concentrations in DOCA-salt rats and also augmented the concentrations of this 
electrolyte in UNX animals (Table 1). 
 
The maximal contractile responses to noradrenaline and relaxant responses to 
acetylcholine in isolated thoracic aortic rings were unchanged in two week DOCA-
salt rats, but were significantly reduced after four weeks of DOCA-salt treatment 
(Figure 3A and B). There was also an increased potency of noradrenaline after both 
two and four weeks of DOCA-salt treatment (Figure 3A, Table 2). Responses to 
sodium nitroprusside were unchanged between groups except in two week DOCA-salt 
animals, where relaxation was augmented at concentrations of 1µM and 3 µM (Figure 
3C). Omapatrilat was without effect in DOCA-salt rats on these indicators of vascular 
function (Figure 3A, B and C, Table 2). 
 
In microelectrode recordings of isolated left ventricular papillary muscles, resting 
membrane potential and action potential amplitude were unchanged in the five study 
groups (Table 3). Two week DOCA-salt rat papillary muscles, however, demonstrated 
prolonged action potentials at 90% of repolarization (APD90). Four week DOCA-salt 
controls exhibited further lengthening of APD90, as well as APD20 and APD50 (Table 
3). Omapatrilat therapy from 2 to 4 weeks of the study period prevented further 
lengthening of APD90 in DOCA-salt rats (Table 3). 
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DISCUSSION 
 
In the treatment of cardiovascular disease, omapatrilat has the advantage of 
concomitantly blocking mitogenic and hypertensive responses to angiotensin II as an 
ACE inhibitor while also stimulating anti-mitogenic and hypotensive mechanisms via 
NEP inhibition. In the current study, we observed that omapatrilat therapy attenuated 
further increases in left ventricular hypertrophy, fibrosis and inflammation, cardiac 
action potential prolongation, and aortic medial hypertrophy without antihypertensive 
action in DOCA-salt rats and without reversing existing remodelling. 
 
Previous studies have shown that omapatrilat reduced blood pressure irrespective of 
renin status (5) with NEP inhibition most valuable in low renin forms of hypertension, 
where ACE inhibition is less effective, such as the DOCA-salt hypertensive rat (5, 19-
21). This is consistent with the observation that hypertension is accelerated in this 
model with administration of antibodies to ANP (22). In the current study, however, 
we showed no change in blood pressure with omapatrilat in DOCA-salt rats using a 
reversal protocol, despite using a relatively high dose of the drug as in the previous 
studies (5,19-21). However, our blood pressure findings must be interpreted with 
caution given the limitations of tail cuff plethysmography versus telemetry. 
Nonetheless, our results are in agreement with Elmarakby et al. (9) who demonstrated 
with telemetry that omapatrilat was ineffective at lowering arterial pressure in the 
DOCA-salt hypertensive rat whether given after the establishment of hypertension, as 
in our study, or for the duration of DOCA-salt treatment. These authors hypothesized 
that abrogated metabolism of endothelin by NEP inhibition (8) may limit the 
antihypertensive effects of the dual ACE/NEP inhibitor in this setting. Consistent with 
this, they found urinary endothelin excretion in DOCA-salt rats increased almost two-
fold with omapatrilat treatment suggesting augmented endothelin survival (9). Thus, 
with the DOCA-salt model characterized by elevated levels of vascular and 
circulating endothelin-1 (23,24) and the peptide implicated in the development and 
maintenance of hypertension in this model (9,12-14,24), omapatrilat therapy may 
potentially increase circulating levels of this potent vasoconstrictor to prevent a 
reduction in blood pressure.  
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However, intervention with omapatrilat attenuated further cardiovascular hypertrophy 
and fibrosis. We have previously shown that cardiac fibrosis, but not hypertrophy, 
associated with DOCA-salt hypertension was corrected by inhibition of the renin-
angiotensin system with the ACE inhibitor captopril, the AT1 receptor antagonist 
candesartan or the aldosterone antagonist spironolactone, without reduction of blood 
pressure (15). Our findings suggest that NEP inhibition may play an additional role in 
the prevention of both cardiac and vascular remodelling, particularly of left 
ventricular and aortic medial hypertrophy. In vitro, natriuretic peptides inhibited the 
hypertrophy and proliferation of cardiomyocytes (25,26), vascular smooth muscle 
cells (27) as well as the proliferation and collagen matrix production by fibroblasts 
(28-30). In vivo, knockout inactivation of the natriuretic peptide receptor (NPR)-A in 
mice (Npr1-/-) increased ventricular mass and fibrosis disproportionately with the 
small rise in blood pressure (31,32), suggesting that natriuretic peptides can regulate 
cardiovascular remodelling independent of blood pressure. Further, given their anti-
mitogenic effects on cardiac fibroblasts and myocytes, there is a possible role for 
bradykinin (33) and adrenomedullin (34,35) in the cardioprotective effects of 
omapatrilat in the current study. 
 
NEP inhibition, and therefore presumably natriuretic peptides, may show anti-
inflammatory responses since treatment with omapatrilat or the NEP inhibitor, CGS 
25462, suppressed the increased expression of NF-κB, monocyte chemotactic protein 
(MCP)-1, surface adhesion molecules and macrophage infiltration associated with 
cardiac fibrosis in DOCA-salt rats (20). This is in agreement with our results, where 
omapatrilat prevented further inflammatory cell infiltration into the left ventricular 
interstitium.  
 
Action potential prolongation is a common electrophysiological disturbance in 
hypertrophied myocardium (36), including DOCA-salt hypertensive rats (37). 
Depression of the calcium-independent transient outward K+ current (Ito) in DOCA-
salt rats was responsible for this prolongation, such that an absence of enhanced Ito 
channel expression concurrent with hypertrophy resulted in a reduced channel density 
per unit surface area (37). Furthermore, non-pharmacological regression of LV 
hypertrophy in DOCA-salt rats normalized the Ito current and APD (37). Thus, the 
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prevention of further cardiac action potential prolongation with omapatrilat is most 
likely secondary to its amelioration of left ventricular hypertrophy. Importantly, this 
improvement in cardiac electrophysiology with omapatrilat would presumably render 
the rats less susceptible to ventricular arrhythmias, as shown with the ACE inhibitor, 
captopril, in a renovascular model of left ventricular hypertrophy (38). 
 
In our study, isolated aortic rings from 4 week DOCA-salt treated rats showed a 
reduced responsiveness to acetylcholine, which acts through an endothelium-
dependent mechanism. This indicates a diminished reactivity of endothelial cells to 
the activation or production of nitric oxide or both. In addition, dual ACE/NEP 
inhibition with omapatrilat failed to attenuate this endothelial dysfunction. This is in 
contrast to previous work where omapatrilat therapy improved endothelial function in 
hypertensive rat models (39-41), including DOCA-salt hypertensive rats (21). Unlike 
our results, these studies also demonstrated hypotensive responses with omapatrilat, 
which is the most likely mechanism responsible for this discrepancy. DOCA-salt (2 
and 4 week) rats also exhibited normal or enhanced responses to the nitric oxide-
donor, SNP, indicating preservation or even augmentation of the downstream 
pathway of nitric oxide, guanylate cyclase (and cGMP) in the vascular smooth muscle 
of these animals.  
 
This study shows that omapatrilat attenuated the signs of further cardiovascular 
remodelling, especially aortic medial thickening, myocardial inflammation and 
fibrosis, left ventricular hypertrophy and action potential prolongation, in DOCA-salt 
hypertensive rats. Further, these effects of omapatrilat may be independent of an anti-
hypertensive action. This suggests that the renin-angiotensin-aldosterone, natriuretic 
peptide and bradykinin systems may be directly involved in the pathogenesis of 
cardiovascular remodelling in the DOCA-salt model of hypertension in rats.  
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Table 1: Physiological parameters in UNX, DOCA-salt and omapatrilat-treated rats. 
 
 UNX UNX+OMA DOCA-salt 
(2 week) 
DOCA-salt 
(4 week) 
DOCA-salt 
+OMA 
Initial body 
weight (g) 
316±5 
(n=8) 
309±4 
(n=10) 
314±2 
(n=12) 
315±3 
(n=13) 
312±6 
(n=11) 
Final body 
weight (g) 
417±5 
(n=8) 
393±7 
(n=10) 
332±7* 
(n=12) 
321±6* 
(n=13) 
340±7* 
(n=11) 
LV+septum 
weight (mg/g) 
1.81±0.04 
(n=8) 
1.74±0.04 
(n=10) 
2.27±0.05*#
(n=12) 
3.00±0.07* 
(n=13) 
2.54±0.07*#
(n=11) 
Remnant 
kidney weight 
(mg/g) 
5.0±0.2 
(n=8) 
4.8±0.1 
(n=10) 
7.5±0.2* 
(n-12) 
10.1±0.5*# 
(n=13) 
9.4±0.3*# 
(n=11) 
Plasma Na+ 
concentration 
(mM) 
129.6±0.5 
(n=10) 
132.5±0.4 
(n=10) 
136.5±0.3* 
(n=10) 
135.6±1.3* 
(n=10) 
136.3±0.8* 
(n=10) 
Plasma K+ 
concentration 
(mM) 
3.5±0.1 
(n=10) 
5.1±0.4* 
(n=10) 
2.2±0.2* 
(n=10) 
1.9±0.2* 
(n=10) 
3.0±0.2#
(n=10) 
Diastolic 
Stiffness 
Constant (κ) 
21.4±0.4 
(n=9) 
21.7±0.4 
(n=9) 
22.1±0.3#
(n=8) 
24.6±0.5* 
(n=9) 
23.2±0.4* 
(n=10) 
Left 
Ventricular 
Hydroxyproline 
Content (mg/g) 
1.07±0.05 
(n=7) 
1.20±0.05 
(n=9) 
1.20±0.08#
(n=10) 
1.60±0.08* 
(n=8) 
1.20±0.05#
(n=10) 
Aortic Media 
Thickness (μm) 
78.5±4.2 
(n=7) 
82.9±3.7 
(n=7) 
91.1±2.5#
(n=7) 
121.6±5.2* 
(n=7) 
103.8±3.7*#
(n=8) 
Inflammatory 
Score 
0.7±0.2 
(n=7) 
0.7±0.2 
(n=8) 
2.4±0.5*# 
(n=7) 
3.8±0.1* 
(n=7) 
2.3±0.2*#
(n=8) 
* p<0.05 compared to UNX, # p<0.05 compared to DOCA-salt (4 week), 
OMA=omapatrilat 
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Table 2: Potency of vascular reactions to noradrenaline, acetylcholine and sodium 
nitroprusside 
 
 UNX 
 
UNX 
+OMA 
DOCA-salt 
(2 week) 
DOCA-salt 
(4 week) 
DOCA-salt 
+OMA 
Noradrenaline   
-log EC50 (M) 
7.1±0.1 
(n=15) 
7.0±0.1 
(n=15) 
7.7±0.1* 
(n=15) 
7.9±0.1* 
(n=15) 
7.8±0.1* 
(n=14) 
Acetylcholine    
-log EC50 (M) 
6.8±0.1 
(n=12) 
6.7±0.1 
(n=14) 
6.6±0.1 
(n=14) 
6.6±0.1 
(n=14) 
6.7±0.1 
(n=14) 
Sodium 
Nitroprusside    
-log EC50 (M) 
7.3±0.1 
(n=15) 
7.5±0.1 
(n=15) 
7.3±0.1 
(n=14) 
7.1±0.1 
(n=14) 
7.3±0.1 
(n=13) 
* p<0.05 compared to UNX; EC50 = concentration giving a half maximal response; 
OMA = omapatrilat
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Table 3: Cardiac electrophysiological parameters in UNX, DOCA-salt and 
omapatrilat-treated rats. 
 
 UNX 
(n=7) 
UNX 
+OMA 
(n=6) 
DOCA-salt 
(2 week) 
(n=9) 
DOCA-salt 
(4 week) 
(n=9) 
DOCA-salt 
+OMA 
(n=9) 
Resting 
Membrane 
Potential (mV) 
-73±3 -74±5 
 
-69±2 
 
-74±2 
 
-75±2 
 
Action Potential 
Amplitude (mV) 
93±3 
 
93±2 
 
87±2 
 
93±3 
 
91±2 
 
APD20 (ms) 8.3±1.1 
 
8.4±0.7 
 
12.5±1.0 
 
17.6±1.9* 
 
14.4±1.5* 
 
APD50 (ms) 18.4±1.6 
 
17.8±1.4 
 
29.6±1.9#
 
45.3±3.9* 
 
38.1±3.0* 
 
APD90 (ms) 50.2±2.1 
 
48.5±3.7 
 
84.1±5.6*#
 
115.1±4.2* 
 
92.8±5.0*#
 
* p<0.05 compared to UNX, # p<0.05 compared to DOCA-salt (4 week); APD20, 
APD50, and APD90 = Action Potential Duration at 20%, 50% and 90% of 
repolarization respectively; OMA = omapatrilat 
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FIGURE 1. 
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FIGURE 2. 
 
 
FIGURE 3.    
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Legends to figures 
 
FIGURE 1: Effect of omapatrilat (OMA) therapy on blood pressure. Data represent the 
comparison of systolic blood pressure in UNX, OMA-treated UNX, DOCA-salt 
hypertensive and OMA-treated DOCA-salt hypertensive groups over the 4 week protocol 
period. Values are mean ± SEM; * p<0.05 vs UNX; # p<0.05 vs DOCA-salt (4 week). 
Numbers in parentheses represent animal numbers. 
 
FIGURE 2: Graphical representations of left ventricular interstitial collagen area (A) and 
perivascular collagen area (B) in UNX, omapatrilat (OMA)-treated UNX, DOCA-salt 
hypertensive (2 and 4 weeks) and OMA-treated DOCA-salt hypertensive groups over the 
4 week protocol period. Values are mean ± SEM; * p<0.05 vs UNX; # p<0.05 vs DOCA-
salt (4 week). Numbers in parentheses represent animal numbers. 
 
FIGURE 3: Concentration-response curves to noradrenaline (A) for UNX (filled square, 
n=15), omapatrilat (OMA)-treated UNX (open square, n=15), 2 week DOCA-salt (open 
circle, n=15), 4 week DOCA-salt (filled triangle, n=15) and OMA-treated DOCA-salt 
(open triangle, n=14). Concentration-response curves to acetylcholine (B) for UNX 
(filled square, n=12), OMA-treated UNX (open square, n=14), 2 week DOCA-salt (open 
circle, n=14), 4 week DOCA-salt (filled triangle, n=14) and OMA-treated DOCA-salt 
(open triangle, n=14). Concentration-response curves to sodium nitroprusside (C) for 
UNX (filled square, n=15), OMA-treated UNX (open square, n=15), 2 week DOCA-salt 
(open circle, n=14), 4 week DOCA-salt (filled triangle, n=14) and OMA-treated DOCA-
salt (open triangle, n=13); * p<0.05 vs UNX. 
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